“I am so grateful for this grant supporting research in meningiomas, the most common primary intracranial tumor. Given two identical appearing meningiomas, one will grow while the other will eventually kill the patient. Radiomics will be able to differentiate between aggressive and “quiet” meningiomas noninvasively. Eventually, we will be able to use the AI analysis to noninvasively predict molecular markers and DNA methylation subtypes and choose appropriate, personalized treatment that will improve patient quality of life and survival.
This grant provides essential support to early researchers. It is an investment that will pay off in future, larger projects that will fuel our endeavors to improve patient safety, make treatments more effective, and improve patients’ lives.”
Comments